Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

McDermott Will & Emery. (1/6/17). "Press Release: McDermott Will & Emery Advised Servier in Its License Option Agreement with OSE Immunotherapeutics". Paris.

Region Region ALL
Organisations Organisation McDermott Will & Emery, Paris
  Today McDermott Will & Emery (MWE) (Group)
  Group McDermott Will & Emery (MWE) (Group)
  Organisation 2 OSE Immunotherapeutics S.A.
  Today OSE Pharma S.A.
  Group OSE Immunotherapeutics (Group)
Products Product legal services
  Product 2 Effi-7 (Effimune/OSE Immunotherapeutics/Servier)
Index terms Index term Servier–McDermott Will & Emery: legal services, 201612 advisor for license option agreem of Servier for Effi-7 with OSE Immunotherapeutics
  Index term 2 Servier–OSE Immunotherapeutics: therapeutic antibody, 201612– license option ww excl up to €272m for Effi-7 immunomodulatory antibody to Servier
Persons Person Paronneau, Anthony (McDermott Will & Emery 201701 Partner in Life Sciences Group in Paris)
  Person 2 Trombe, Emmanuelle (McDermott Will & Emery 201701 Partner in Life Sciences Group in Paris)

International law firm McDermott Will & Emery advised French-based Servier, an international pharmaceutical company, in its license option agreement with OSE Immunotherapeutics on the exclusive worldwide rights for the development and commercialization of the Effi-7 product. Effi-7 is a monoclonal immunomodulatory antibody.

OSE Immunotherapeutics is eligible to receive up to €272 million upon the exercise of a two-steps option license. These steps will enable the development of Effi-7 up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease.

The McDermott team advising on the transaction comprised of Paris-based partners Emmanuelle Trombe and Anthony Paronneau, along with associates Raphaëlle Monjou and Louise Aberg.

McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.

About McDermott Will & Emery

McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.

Related Professionals

Louise Aberg
Associate Paris
Raphaëlle Monjou
Associate Paris
Anthony Paronneau
Partner Paris
Emmanuelle Trombe
Partner Paris

Related Experience

Life Sciences
Licensing & Collaborative Arrangements

Record changed: 2023-06-05


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for McDermott Will & Emery (MWE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top